Publication: Persistence of hepatitis B immune memory until 9–10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months
Issued Date
2018-05-04
Resource Type
ISSN
2164554X
21645515
21645515
Other identifier(s)
2-s2.0-85042214406
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Human Vaccines and Immunotherapeutics. Vol.14, No.5 (2018), 1257-1265
Suggested Citation
Pope Kosalaraksa, Kulkanya Chokephaibulkit, Suwat Benjaponpitak, Chitsanu Pancharoen, Sunate Chuenkitmongkol, Siham B'Chir, Xavier Da Costa, Emmanuel Vidor Persistence of hepatitis B immune memory until 9–10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months. Human Vaccines and Immunotherapeutics. Vol.14, No.5 (2018), 1257-1265. doi:10.1080/21645515.2018.1426418 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46017
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Persistence of hepatitis B immune memory until 9–10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months
Abstract
© 2018 The Author(s). Published with license by Taylor & Francis © 2018, © Pope Kosalaraksa, Kulkanya Chokephaibulkit, Suwat Benjaponpitak, Chitsanu Pancharoen, Sunate Chuenkitmongkol, Siham B'Chir, Xavier Da Costa, and Emmanuel Vidor. Objective: To evaluate the long-term persistence of anti-hepatitis B surface (HBs) antibodies and the response to a HB challenge re-vaccination in children who had received a primary series of DTaP-IPV-HB-PRP∼T (Hexaxim™) or DTaP-IPV-HB/PRP∼T (Infanrix hexa™). Methods: Two cohorts of participants who had previously received HB vaccine at birth followed by either DTaP-IPV-HB-PRP∼T or DTaP-IPV-HB/PRP∼T co-administered with PCV7 at 2, 4, 6 months of age in a randomized, Phase III, observer-blind study in Thailand, were followed up for anti-HBs antibodies (geometric mean concentrations [GMCs] and seroprotection [SP] rate [% of participants with a titer ≥10 mIU/mL]) at 12–18 months of age and 9–10 years of age. A monovalent HB challenge re-vaccination was administered at 9–10 years of age and the anamnestic response was evaluated. Results: Anti-HBs GMCs and SP rates in the DTaP-IPV-HB-PRP∼T and DTaP-IPV-HB/PRP∼T groups were high and similar post-primary vaccination series (2477 mIU/mL and 99.5% and 2442 mIU/mL and 99.5%, respectively) and declined to a similar extent in each group at 12–18 months (154.5 mIU/mL and 90.8% and 162.3 mIU/mL and 96.5%, respectively). Antibody levels further declined at 9–10 years of age (13.3 mIU/mL and 49.3% and 8.0 mIU/mL and 42.9%) and a strong anamnestic response occurred in each group post-HB challenge re-vaccination (92.8% and 98.7%, respectively). Conclusion: The kinetics of long-term anti-HBs antibody persistence were similar following a primary series of DTaP-IPV-HB-PRP∼T or DTaP-IPV-HB/PRP∼T. The response to a subsequent HB challenge re-vaccination was strong and similar in each group, demonstrating persisting immune memory.